Palisade Bio to Present Data on PDE4 Inhibitor PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium

Palisade Bio will present data regarding the therapeutic potential of its drug candidate, PALI-2108, for the treatment of fibrostenotic Crohn’s disease at an upcoming New York Academy of Sciences symposium. The presentation will outline the mechanism and clinical objectives of the investigational therapy as the company continues its research into gastrointestinal conditions.

The symposium provides a platform for Palisade Bio to share technical details concerning PALI-2108, a phosphodiesterase-4 (PDE4) inhibitor designed to address the fibrotic complications associated with Crohn’s disease. Fibrostenotic Crohn’s disease involves the narrowing of the intestine due to the buildup of scar tissue, a condition for which there are currently limited non-surgical treatment options. By targeting the underlying inflammatory and fibrotic pathways, the drug aims to mitigate the progression of these strictures. The company’s presentation will focus on the scientific rationale behind the development of this candidate and its intended role in managing the disease.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 9, 2026

Author

GOAI